MARKET

HTBX

HTBX

Heat Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.190
+0.020
+1.71%
After Hours: 1.180 -0.01 -0.84% 19:56 10/28 EDT
OPEN
1.130
PREV CLOSE
1.170
HIGH
1.230
LOW
1.110
VOLUME
5.98M
TURNOVER
--
52 WEEK HIGH
4.300
52 WEEK LOW
0.1950
MARKET CAP
176.79M
P/E (TTM)
-2.6766
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Shareholders Are Thrilled That The Heat Biologics (NASDAQ:HTBX) Share Price Increased 117%
Some Heat Biologics, Inc. (NASDAQ:HTBX) shareholders are probably rather concerned to see the share price fall 49...
Simply Wall St. · 13h ago
NIO, BBBY GME and GRUB among premarket gainers
Interpace Biosciences (IDXG) +72% after completing an independent investigation into complaints and finds it unsubstantiated.Allscripts Healthcare Solutions (MDRX) +38% on announcing to sell its CarePort Health business to WellSky.VOXX International Corporation (VOXX) +17% on Q2 results.Taiwan
Seekingalpha · 10/14 12:21
Heat Biologics secures new patent related to gp96 platform
Heat Biologics (HTBX) has been issued a new US patent (Patent No. 10,780,161) covering compositions of matter that are part of Heat's gp96 platform in combination with inducible T cell
Seekingalpha · 10/07 12:19
Heat Biologics Issued Additional Patent On gp96 Combination Platform Therapy With T-Cell Co-Stimulator
New patent covers ICOS T cell co-stimulation in combination with Heat's proprietary gp96 platform DURHAM, NC / ACCESSWIRE / October 7, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a
Benzinga · 10/07 11:38
Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator
New patent covers ICOS T cell co-stimulation in combination with Heat's proprietary gp96 platformDURHAM, NC / ACCESSWIRE / October 7, 2020 / Heat Biologics, Inc.
ACCESSWIRE · 10/07 11:30
HTBX: Breaking into the Big Leagues: $100 Million + 3 Clinical Candidates
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Heat Biologics, Inc. (NASDAQ:HTBX) has made substantial progress this year with the entry of HS-130 and PTX-35 into the clinic. Substantial preclinical work has also taken place for a coronavirus vaccine which may enter the clinic
Zacks Small Cap Research · 09/16 10:37
Heat Biologics CEO To Participate In Virtual Panel: 'New Approaches to COVID-19: Hidden Breakthroughs,' On Thursday, September 10th
DURHAM, NC / ACCESSWIRE / September 9, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune
Benzinga · 09/09 11:33
Precipio, AnPac Bio-Medical Science leads the gainers pack, Cardiff Oncology, Fulgent Genetics amongst major losers
Gainers: Precipio (PRPO) +15%, AnPac Bio-Medical Science Co (ANPC) +15%, The Cooper Companies (COO) +7%, Entasis Therapeutics Holdings (ETTX) +6%, 89bio (ETNB) +5%.Losers: Cardiff Oncology (CRDF) -26%, Heat Biologics (HTBX) -16%, Fulgent Genetics (FLGT) -15%, Sorrento Therapeutics (SRNE) -13%, Xeris Pharmaceuticals (XERS) -12%.
Seekingalpha · 09/04 15:04
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HTBX. Analyze the recent business situations of Heat Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HTBX stock price target is 4.750 with a high estimate of 5.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 28
Institutional Holdings: 10.60M
% Owned: 7.13%
Shares Outstanding: 148.56M
TypeInstitutionsShares
Increased
11
4.44M
New
12
83.81K
Decreased
3
1.59M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Chief Executive Officer/Director
Jeffrey Wolf
Chief Operating Officer/Chief Scientific Officer
Jeff Hutchins
Vice President - Finance/Secretary
William Ostrander
Lead Director/Independent Director
John Prendergast
Independent Director
John Monahan
Independent Director
Edward Smith
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HTBX
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Heat Biologics Inc stock information, including NASDAQ:HTBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HTBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HTBX stock methods without spending real money on the virtual paper trading platform.